Glaxosmithkline Pharmaceuticals Ltd (GLAXO) is currently trading at 2,347.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

GlaxoSmithKline Pharmaceuticals Limited (GSK), a subsidiary of the UK-based GSK Plc, primarily engages in manufacturing and trading pharmaceutical products and vaccines. Operating with a strong presence in India, GSK focuses on segments like general medicines, vaccines, and specialization in oncology. The recent launch of Jemperli and Zejula marks GSK's strategic re-entry into the oncology market, addressing unmet needs in gynecological cancers such as endometrial and ovarian cancers, signaling a robust commitment to innovation in cancer therapies. GSK's strategic acquisition of Novartis' vaccines business has significantly bolstered its vaccine portfolio, highlighting the company's pursuit of expanding its virology expertise and reinforcing its global position in the vaccines market. Despite facing supply chain disruptions and regulatory impacts, GSK demonstrated resilience with significant growth in its specialty and vaccines segments, achieving improved profit margins and a robust portfolio transformation. The company has showcased a strong cultural transformation with a focus on driving growth through digital innovation and partnerships with healthcare providers, especially in the adult immunization segment.

Over the past 52 weeks, Glaxosmithkline Pharmaceuticals Ltd has traded between a low of ₹1,924.30 and a high of ₹3,515.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Glaxosmithkline Pharmaceuticals Ltd has a market capitalization of approximately 39,788.40. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Glaxosmithkline Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 41.74 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

You can buy shares of Glaxosmithkline Pharmaceuticals Ltd (GLAXO) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.

Based on its market capitalization of 39,788.40 Cr, Glaxosmithkline Pharmaceuticals Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Glaxosmithkline Pharmaceuticals Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Glaxosmithkline Pharmaceuticals Ltd is 41.74. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Glaxosmithkline Pharmaceuticals Ltd pays dividends with a current dividend yield of 2.30%. Dividend-paying stocks may provide periodic income in addition to potential long-term capital appreciation.

Key risks associated with Glaxosmithkline Pharmaceuticals Ltd include sector-specific challenges in the Pharmaceuticals industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.